Financial Toxicity - An Overlooked Side Effect

Overview

Journal Gynecol Oncol

Date 2018 May 21

PMID 29778508

Citations 10

Authors

Margaret I Liang

Warner K Huh

Affiliations

Soon will be listed here.

Citing Articles

A Financial Toxicity Screening and Care Coordination Quality Improvement Program in a Gynecology Oncology Urban Practice.

Harris T, Brinzo J, Pell C J Adv Pract Oncol. 2024; 15(1):16-27.

PMID: 39055367 PMC: 11173661. DOI: 10.6004/jadpro.2024.15.1.2.

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer.

Smith A, Apple A, Hugo A, Haggerty A, Ko E Gynecol Oncol Rep. 2024; 52:101335.

PMID: 38390624 PMC: 10878851. DOI: 10.1016/j.gore.2024.101335.

Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer.

Xu B, So W, Choi K Support Care Cancer. 2024; 32(2):136.

PMID: 38279988 PMC: 10821980. DOI: 10.1007/s00520-024-08320-w.

Economic hardships from COVID-19 and its association with socioeconomic factors and diabetes management indicators: A cross-sectional study.

Xin Y, Duman E, Yan X, Gong E, Xiong S, Chen X Heliyon. 2022; 8(5):e09461.

PMID: 35601227 PMC: 9113763. DOI: 10.1016/j.heliyon.2022.e09461.

Impact of Cost Conversation on Decision-Making Outcomes.

Espinoza Suarez N, LaVecchia C, Fischer K, Kamath C, Brito J Mayo Clin Proc Innov Qual Outcomes. 2021; 5(4):802-810.

PMID: 34401656 PMC: 8358194. DOI: 10.1016/j.mayocpiqo.2021.05.006.

References

Langa K, Fendrick A, Chernew M, Kabeto M, Paisley K, Hayman J . Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004; 7(2):186-94. DOI: 10.1111/j.1524-4733.2004.72334.x. View

Himmelstein D, Thorne D, Warren E, Woolhandler S . Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009; 122(8):741-6. DOI: 10.1016/j.amjmed.2009.04.012. View

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-92. DOI: 10.1056/NEJMoa1105535. View

Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K . Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013; 32(6):1143-52. PMC: 4240626. DOI: 10.1377/hlthaff.2012.1263. View

de Souza J, Yap B, Hlubocky F, Wroblewski K, Ratain M, Cella D . The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014; 120(20):3245-53. DOI: 10.1002/cncr.28814. View

Ramsey S, Bansal A, Fedorenko C, Blough D, Overstreet K, Shankaran V . Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. J Clin Oncol. 2016; 34(9):980-6. PMC: 4933128. DOI: 10.1200/JCO.2015.64.6620. View

Kale H, Carroll N . Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016; 122(8):283-9. DOI: 10.1002/cncr.29808. View

10.

Schnipper L, Davidson N, Wollins D, Blayney D, Dicker A, Ganz P . Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016; 34(24):2925-34. DOI: 10.1200/JCO.2016.68.2518. View

11.

Kesselheim A, Avorn J, Sarpatwari A . The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016; 316(8):858-71. DOI: 10.1001/jama.2016.11237. View

12.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

13.

Zafar S, Peppercorn J . Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?. J Clin Oncol. 2017; 35(19):2113-2116. PMC: 6553813. DOI: 10.1200/JCO.2016.71.7280. View

14.

Pujade-Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A . Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9):1274-1284. DOI: 10.1016/S1470-2045(17)30469-2. View

15.

Hunter W, Zafar S, Hesson A, Davis J, Kirby C, Barnett J . Discussing Health Care Expenses in the Oncology Clinic: Analysis of Cost Conversations in Outpatient Encounters. J Oncol Pract. 2017; 13(11):e944-e956. PMC: 5684881. DOI: 10.1200/JOP.2017.022855. View

16.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

17.

Doshi J, Li P, Huo H, Pettit A, Armstrong K . Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. J Clin Oncol. 2017; 36(5):476-482. DOI: 10.1200/JCO.2017.74.5091. View

18.

Shalowitz D, Cohn D . Cancer care delivery research in gynecologic oncology. Gynecol Oncol. 2018; 148(3):445-448. PMC: 10627414. DOI: 10.1016/j.ygyno.2017.12.027. View

19.

Carrera P, Kantarjian H, Blinder V . The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018; 68(2):153-165. PMC: 6652174. DOI: 10.3322/caac.21443. View